Related references
Note: Only part of the references are listed.Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study
Robert Wesolowski et al.
ONCOLOGIST (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J. Gray et al.
GYNECOLOGIC ONCOLOGY (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee et al.
CLINICAL CANCER RESEARCH (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H. Wilson et al.
BRITISH JOURNAL OF CANCER (2017)
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Eve T. Rodler et al.
CLINICAL CANCER RESEARCH (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer
Lawrence Leichman et al.
ONCOLOGIST (2016)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
DNA double strand break repair pathway choice: a chromatin based decision?
T. Clouaire et al.
NUCLEUS (2015)
DNA double strand break repair pathway choice: a chromatin based decision?
T. Clouaire et al.
NUCLEUS (2015)
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma
Sonja J. Gill et al.
PLOS ONE (2015)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
J. Balmana et al.
ANNALS OF ONCOLOGY (2014)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Makiko Tahara et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Causes and consequences of replication stress
Michelle K. Zeman et al.
NATURE CELL BIOLOGY (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Anand G. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
INTEGRATED GENOMIC ANALYSIS OF OVARIAN CARCINOMA
[Anonymous]
CANCER DISCOVERY (2011)
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration
Ganta Vijay Chaitanya et al.
CELL COMMUNICATION AND SIGNALING (2010)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
